AQST (STOCKS)
Aquestive Therapeutics, Inc. Common Stock
$4.205000
+0.055000 (+1.33%)
Prev close: $4.150000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Daniel Barber
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $513.20M
- Employees
- 142
- P/E (TTM)
- -5.34
- P/B (TTM)
- -15.05
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
4
Strong Buy
10
Buy
1
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Dec 2025 (Q4)
|
$-0.15 | $-0.14 | -0.0148 | -10.95% |
|
Sep 2025 (Q3)
|
$-0.14 | $-0.14 | -0.0048 | -3.55% |
|
Jun 2025 (Q2)
|
$-0.14 | $-0.17 | +0.0317 | +18.46% |
|
Mar 2025 (Q1)
|
$-0.24 | $-0.17 | -0.0666 | -38.41% |
Financial Statements
| Revenues | $44.55M |
| Benefits Costs and Expenses | $128.33M |
| Cost Of Revenue | $18.56M |
| Costs And Expenses | $115.60M |
| Gross Profit | $25.99M |
| Operating Expenses | $97.04M |
| Selling, General, and Administrative Expenses | $79.85M |
| Depreciation and Amortization | $548.00K |
| Research and Development | $17.19M |
| Operating Income/Loss | -$71.05M |
| Income/Loss From Continuing Operations After Tax | -$83.78M |
| Income/Loss From Continuing Operations Before Tax | -$83.78M |
| Income Tax Expense/Benefit | $0.00 |
| Income Tax Expense/Benefit, Current | $0.00 |
| Income Tax Expense/Benefit, Deferred | $0.00 |
| Net Income/Loss | -$83.78M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$83.78M |
| Net Income/Loss Available To Common Stockholders, Basic | -$83.78M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$0.78 |
| Diluted Earnings Per Share | -$0.78 |
| Basic Average Shares | 106,926,528 |
| Diluted Average Shares | 106,926,528 |
| Assets | $160.43M |
| Current Assets | $149.27M |
| Accounts Receivable | $17.76M |
| Inventory | $6.17M |
| Other Current Assets | $125.34M |
| Noncurrent Assets | $11.16M |
| Fixed Assets | $3.89M |
| Other Non-current Assets | $7.26M |
| Liabilities | $194.09M |
| Current Liabilities | $47.61M |
| Accounts Payable | $29.86M |
| Wages | $3.71M |
| Other Current Liabilities | $14.04M |
| Noncurrent Liabilities | $146.48M |
| Long-term Debt | $45.00M |
| Other Non-current Liabilities | $101.48M |
| Equity | -$33.66M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | -$33.66M |
| Liabilities And Equity | $160.43M |
| Net Cash Flow From Operating Activities | -$52.43M |
| Net Cash Flow From Operating Activities, Continuing | -$52.43M |
| Net Cash Flow From Investing Activities | -$562.00K |
| Net Cash Flow From Investing Activities, Continuing | -$562.00K |
| Net Cash Flow From Financing Activities | $102.62M |
| Net Cash Flow From Financing Activities, Continuing | $102.62M |
| Net Cash Flow | $49.62M |
| Net Cash Flow, Continuing | $49.62M |
| Comprehensive Income/Loss | -$83.78M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$83.78M |
| Other Comprehensive Income/Loss | -$83.78M |